Prostate Cancer Clinical Trials Creating New Treatment Options for Patients

Clinical Trials E-Newsletter | February 2018

Clinical Trial e-Newsletter

Prostate Cancer Clinical Trials Are Creating

New Treatment Options For Patients

FDA Approves “Apalutimide” for Non-metastatic Castration-Resistant Prostate Cancer

For the first time, the Federal Drug Administration (FDA) has approved a medication for the treatment of non-metastatic castration-resistant prostate cancer (CRPC). Apalutimide , the new drug is based on the results of the Phase 3 SPARTAN clinical trial which was sponsored by Janssen .

Xtandi Reduces Risk of Metastasis in Castration-resistant Prostate Cancer

The Phase 3 PROSPER clinical trial evaluated whether adding Xtandi to the standard androgen deprivation therapy (ADT) was better than ADT alone in patients whose cancer had progressed based on rising PSA levels. The combination extended the time a patient remained alive and metastasis-free by nearly two years, compared to ADT alone.

The trial was conducted by Pfizer and Astellas Pharma. Read More

FDA Approves Zytiga Plus Prednisone for Earlier Form of Metastatic Prostate Cancer

Zytiga (abiraterone acetate) is now approved in the U.S. to treat metastatic high-risk castration-sensitive prostate cancer (CSPC) in combination with prednisone, Janssen Pharmaceutical Companies announced. The U.S. Food and Drug Administration (FDA) granted its approval following results of the Phase 3 LATITUDE clinical trial.